Skip to content
Screener

Shares (Diluted) at other companies

IAR
Integra LifeSciencesIART
78.2M+1.9%
MiMedx Group logo
MiMedx GroupMDXG
147.8M-1.0%
SANUWAVE Health, Inc. logo
SANUWAVE Health, Inc.SNWV
8.6M-6.2%
Axogen logo
AxogenAXGN
53.3M+11.2%
Solventum logo
SolventumSOLV
173.3M-1.1%
InfuSystem Holdings logo
InfuSystem HoldingsINFU
20.9M-1.1%

Other financials

Income statement

See full
Revenue$43.8M-56.7%
Gross profit$63.0M-22.5%
Operating income-$51.0M-305%
Net income-$96.3M-925%
EPS (diluted)-$0.77-670%

Balance sheet

See full
Cash & equivalents$46.1M-36.9%
Total debt$36.6M+19.2%
Total equity$148.3M-36.4%
Total assets$406.4M-11.9%

Cash flow

See full
Operating cash flow-$31.7M+3.7%
CapEx$1.1M-69.8%
Free cash flow-$32.8M+10.3%

Valuation

See full
Market cap$239.33M-59.1%
Enterprise value$229.8M-57.7%
P/S0.5×-0.8×

Profitability

See full
Gross margin75.9%+0.8pp
Operating margin-7.8%
Net margin-18.4%-20.8pp
FCF margin6.9%

Returns & leverage

See full
Return on equity-44.1%-48.0pp
Debt / equity0.2×+0.1×
Current ratio3.5×-0.4×

Where this comes from

Reported directly by Organogenesis Holdings Inc. in its filing.

Tagged under the XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding.

The source filing: Organogenesis Holdings Inc.’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 4:15 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-338049
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Numerator:
Net loss$(96,267)$(9,392)$(149,423)$(28,235)
Accretion of redeemable convertible preferred stock to redemption value(170)(129)(329)(250)
Cumulative dividend on redeemable convertible preferred stock(2,902)(2,681)(5,746)(5,308)
Net loss attributable to common stockholders$(99,339)$(12,202)$(155,498)$(33,793)
Denominator:
Weighted average common shares outstanding —basic and diluted128,674,548126,853,536128,238,204126,576,130
Net loss per share—basic and diluted$(0.77)$(0.10)$(1.21)$(0.27)

Item 1. Unaudited Condensed Consolidated Financial Statements.

FAQ

What is Organogenesis Holdings Inc.'s shares (diluted)?
Organogenesis Holdings Inc. (ORGO) reported shares (diluted) of 128.7M in Q2 2026.
How has Organogenesis Holdings Inc.'s shares (diluted) changed year-over-year?
Organogenesis Holdings Inc.'s shares (diluted) increased by 1.4% year-over-year, from 126.9M to 128.7M.
What is the long-term trend for Organogenesis Holdings Inc.'s shares (diluted)?
Over 4 years (2021 to 2025), Organogenesis Holdings Inc.'s shares (diluted) has grown at a -1.0% compound annual growth rate (CAGR), from 535M to 514.2M.
What does shares (diluted) mean?
The weighted-average shares outstanding plus all potentially dilutive shares from stock options, RSUs, convertible securities, and warrants, using the treasury stock method.

Ask your AI about Organogenesis Holdings Inc.'s shares (diluted).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude